Previously available in Europe under a CE mark, the self-expanding Portico valve and its minimally invasive FlexNav delivery system are designed for patients with severely narrowed aortic heart valves and used in cases where open-heart surgery may be too risky.nThe FDA’s approval closes a gap in Abbott’s structural heart portfolio, which includes treatments like the MitraClip implant for mitral valve regurgitation and the Amplatzer Amulet for mitigating stroke risk due to atrial fibrillation.